1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

New appointment at Versartis

 
• By Zoë Dann

Versartis (US), an emerging biotechnology company developing therapeutics for metabolic diseases and endocrine disorders, has appointed Paul Westberg senior vice-president of business development. He was most recently vice-president of business development at Bayhill Therapeutics, and has also worked at Collabra Pharma, Deltagen and Genentech. Versartis is planning to initiate its first clinical trial of its lead product candidate VRS-859 in type 2 diabetes in the second half and to have top-line results by the end of the year.

Versartis (US), an emerging biotechnology company developing therapeutics for metabolic diseases and endocrine disorders, has appointed Paul Westberg senior vice-president of business development. He was most recently vice-president of business development at Bayhill Therapeutics, and has also worked at Collabra Pharma, Deltagen and Genentech. Versartis is planning to initiate its first clinical trial of its lead product candidate VRS-859 in type 2 diabetes in the second half and to have top-line results by the end of the year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

More from Therapeutic Category

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.